Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma’s “Black Wednesday”: Quarterly Reports Underscore Uncertainty

Executive Summary

An unprecedented string of poor third-quarter earnings reports from the top pharmaceutical companies illustrates the importance of the Medicare debate to the future of the drug industry

You may also be interested in...



J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan

Johnson & Johnson expects its pharmaceutical employee headcount to remain constant in 2004

J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan

Johnson & Johnson expects its pharmaceutical employee headcount to remain constant in 2004

Pfizer Ready To Settle Neurontin Promotion Case; Reserves $427 Mil.

Pfizer expects to pay over $400 mil. to resolve the Boston U.S. Attorney's investigation of Neurontin promotions

Related Content

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel